

## — S-281 —

### The development of pancytopenia secondary to methotrexate therapy in patients with impaired renal function

Department of Internal medicine, College of medicine, The Catholic University of Korea, Seoul, Korea

\*Sun Hee Ko M.D., Seung Min Jung M.D., Eun Jung Shin M.D., Su Hyun Kim M.D., Hye Eun Yoon M.D., Yong Kyun Kim M.D.,  
Bum Soon Choi M.D., Yong Soo Kim M.D., Byung Kee Bang M.D., Chul Woo Yang M.D.

Abstract Methotrexate (MTX) has been considered as the effective treatment for the patients who have moderate to severe rheumatoid arthritis. Severe adverse effects of low-dose MTX are relatively rare. But the present case shows low -dose MTX could cause severe adverse effects, especially pancytopenia is associated with considerable morbidity and potentially life-threatening, to a patient with chronic kidney disease. We experienced 3 cases of pancytopenia secondary to low dose MTX treatment for rheumatoid arthritis patients with chronic renal insufficient. Two patients were at the end stage of renal disease (hemodialysis & peritoneal dialysis, respectively) and the other one was at stage 4 of chronic kidney disease. Mean cumulative MTX dose and treatment duration for all 3 patients was 25mg and 10 days respectively. All cases showed that stomatitis and pancytopenia, which was found at admission in two cases and the other one in 4 days after admission. All patients have recovered from their hematologic complications within 10days of proper care. This shows that MTX treatment should be a contraindication in CKD patients

## — S-282 —

### 만성 신부전 환자에서 발생한 allopurinol에 의한 재생 불량성 빈혈 1예

인제대학교 의과대학 내과학교실<sup>1</sup>, 진단검사의학과학교실<sup>2</sup>

\*유충현<sup>1</sup> · 박석주<sup>1</sup> · 이정녀<sup>2</sup> · 강선우<sup>1</sup> · 김영훈<sup>1</sup> · 김양욱<sup>1</sup>

Aplastic anemia is very rare complication of allopurinol. We experienced an unusual case of aplastic anemia caused by allopurinol therapy for hyperuricemia in a patient with chronic kidney disease. A 37-year-old female patient diagnosed as CKD stage3 was admitted with pancytopenia. she had a history of taking allopurinol for 6 months. Her bone marrow showed low cellularity(<20%) and there were no malignant cell infiltration. She had been free from any infections, including parvovirus B19, CMV and EBV. These results suggest a diagnosis of aplastic anemia. Allopurinol was discontinued immediately and she was treated with blood transfusion and prednisolone. Pancytopenia was improved and bone marrow was done repeatedly. Cellularity was above 70%. We report the first case of aplastic anemia induced by allopurinol in Korea.